Who is sponsoring NCT05667532?

NCT05667532 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05667532?

Interventions in NCT05667532: Contrast Enhanced Mammography.

What condition does NCT05667532 study?

NCT05667532 studies Breast Cancer.

Is NCT05667532 still recruiting?

NCT05667532 is currently recruiting now. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT05667532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Recruiting now NA Last updated 9 January 2026

What this trial tests

NA trial testing Contrast Enhanced Mammography in Breast Cancer in 1,000 participants. Currently enrolling.

Timeline

5 December 2022

Primary endpoint
31 December 2026

31 December 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	1,000
Start date	5 December 2022
Primary completion	31 December 2026
Estimated completion	31 December 2028
Sites	1 location across United States

Drugs / interventions tested

Contrast Enhanced Mammography

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 30 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Contrast Enhanced Mammography

Trials testing the same drug.

NCT06217458 — The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS · NA · not yet recruiting
NCT04579107 — KARMA Kontrast Evaluating Contrast Enhanced Mammography in Early Detection of Breast Cancer · NA · unknown
NCT06311695 — Contrast-Enhanced Spectral Mammography (CESM) · Phase 2 · unknown

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05667532 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing